摘要
背景与目的:放射性脑损伤标志物的研究正在深入。本文探讨S100能否作为脑肿瘤对脑组织的损伤及脑肿瘤放射治疗中放射性脑损伤的生物学标志。方法:临床选择57例脑肿瘤患者,年龄17～69岁,平均46.7岁,男31例,女26例(其中行MRI检查30例,CT检查27例),所有患者经影像学或术后病理证实,其中脑胶质瘤20例,脑转移瘤21例,脑肿瘤单纯行放射治疗16例,所有患者且均行MRI或CT平扫及增强扫描,根据MRI、CT等影像结果测定肿瘤的最大径、肿瘤体积及判定瘤体周围水肿程度;同时抽取每位受检者静脉血3ml,分离血清,采用酶联免疫吸附法检测脑肿瘤患者及脑肿瘤单纯放疗结束后患者外周血中S100B蛋白水平。结果:放疗组患者外周血S100B蛋白含量明显高于脑胶质瘤组及脑MT组,分别(P<0.05)。正常组、脑MT组及脑胶质瘤组患者外周血S100B含量比较,差异无显著性(P>0.05)。肿瘤体积、最大径与血清S100B水平无线性相关,Ⅰ°和Ⅲ°水肿程度的血清S100B水平之间比较,差异有显著性(P=0.028)。结论:S100B蛋白不能作为脑胶质瘤与脑转移瘤的鉴别指标,可以作为脑肿瘤放射治疗导致放射性脑损伤的生物标志。
BACKGROUND ＆ OBJECTIVE ：To evaluate the relationship between serum S100B protein and brain tumor and radiation-induced brain Injury. METHODS： There were total of 57 patients age from 17 to 69 years（mean age 46.7 years,31 men and 26 women）.Thirty one patients underwent MRI examination and 26 patients underwent CT examination. All were proven radiologically and pathologically. There were 20 glioma, 21 metastatic tumors and 16 cases post-radiotherapy brain tumors . The distance,volume and edema degree around the brain tumor were measured .Serum S100B protein levels were detected by Enzyme-Linked Immunoadsorbent Assay （ELISA） in all patients with glioma, brain metastasis and post-radiotherapy. RESULTS：The serum S100B protein level of the post-radiotherapy group was higher than glioma, brain metastasis, health control groups. There were no significant difference among the level of S100B protein in the other three groups（P〉0.05）; The serum S100B proteins level was significantly different between the group with Ⅰ℃and Ⅲ edama degree （P=0.028）. CONCLUSION： Serum S100B protein may serve as a biology marker for radiation-induced brain Injury. In addition ,there are important value to evaluate the edama degree around the brain tumor.
出处
《中国神经肿瘤杂志》
2008年第1期30-34,共5页
Chinese Journal of Neuro-Oncology
